美国 · 股市与财经 · The Motley Fool

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

来源：The Motley Fool · 美国 8 小时前

BioNTech announced that it was stopping a Phase 2 clinical trial for autogene cevumeran, which it was testing as an adjuvant treatment for certain patients with colorectal cancer.…

在 The Motley Fool 阅读全文登录后可收藏

MediaNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.fool.com)

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

推荐阅读

Bessent warns Zelenskyy to 'be very careful' about claims U.S. is throttling Starlink

What Is Starshield, SpaceX’s Military-Grade Satellite Internet Service Ukraine Relies On?

Everyone’s watching the Elizabeth Holmes documentary ‘You Can See Everything’

The Nuclear Power Shortcut That Could Add Gigawatts to the U.S. Grid

Anthropic commits billions to a 'public benefit fund'

‘Street Fighter’ hits $31M in box office debut as moviegoing jumps 48%

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

分享

推荐阅读

Bessent warns Zelenskyy to 'be very careful' about claims U.S. is throttling Starlink

What Is Starshield, SpaceX’s Military-Grade Satellite Internet Service Ukraine Relies On?

Everyone’s watching the Elizabeth Holmes documentary ‘You Can See Everything’

The Nuclear Power Shortcut That Could Add Gigawatts to the U.S. Grid

Anthropic commits billions to a 'public benefit fund'

‘Street Fighter’ hits $31M in box office debut as moviegoing jumps 48%